PRESS RELEASE published on 03/18/2025 at 18:00, 1 year 7 months ago Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion NV receives transparency notifications from Atlas Special Opportunities, LLC regarding selling of voting securities, crossing thresholds. Developing ophthalmic therapies for retinal disease Atlas Special Opportunities Ophthalmic Therapies Oxurion NV Retinal Disease Transparency Notifications
BRIEF published on 03/04/2025 at 19:05, 1 year 7 months ago Oxurion Extends Financing Agreement With Atlas Convertible Bonds Market Capitalization Atlas Special Opportunities Oxurion Financing Program
PRESS RELEASE published on 03/04/2025 at 19:00, 1 year 7 months ago Oxurion Extends Its Financing Program Oxurion NV signs third amendment to convertible bond subscription agreement with Atlas Special Opportunities II, LLC, extending issuance period and clarifying maturity terms Amendment Convertible Bond Oxurion NV Atlas Special Opportunities II Financing Terms
BRIEF published on 02/14/2025 at 19:05, 1 year 8 months ago Oxurion Enhances Board with Nelly Souleymane's Appointment Innovation Board Changes Biopharmaceutical Diversity Oxurion
PRESS RELEASE published on 02/14/2025 at 19:00, 1 year 8 months ago Oxurion strengthens its Board of Directors with the arrival of Nelly Souleymane Oxurion NV announces changes in Board of Directors with the departure of two members and the integration of Nelly Souleymane, strengthening governance and strategic expertise in communication Board Of Directors Governance Communication Oxurion NV Nelly Souleymane
BRIEF published on 01/20/2025 at 18:05, 1 year 9 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Notification Share Acquisition Atlas Special Opportunities Oxurion Retinal Disease Therapies
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 9 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV receives transparency notification regarding shares ownership from Atlas Special Opportunities, LLC, crossing the 20% threshold. Company engaged in developing ophthalmic therapies Transparency Notification Ophthalmic Therapies Oxurion NV Shares Ownership Belgian Transparency Legislation
BRIEF published on 01/14/2025 at 18:05, 1 year 9 months ago Oxurion Receives Transparency Update from Atlas Special Opportunities LLC Actions Transparency Atlas Biopharmaceutical Oxurion
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 9 months ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC Oxurion NV announces receiving an amended transparency notification regarding share ownership by Atlas Special Opportunities, LLC, crossing under the 3% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Retinal Disease
BRIEF published on 01/13/2025 at 18:05, 1 year 9 months ago Oxurion Updates Voting Rights Following Convertible Bond Conversion Voting Rights Convertible Bonds Capital Increase Market Opportunities Oxurion
Published on 10/30/2026 at 23:35, 1 day 4 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 4 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 8 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 12 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 11 hours 4 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 4 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 9 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 4 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 15 hours ago Capital increase through exercise of subscription rights
